Spero Therapeutics (SPRO) Current Leases (2019 - 2026)

Spero Therapeutics (SPRO) has 8 years of Current Leases data on file, last reported at $2.0 million in Q1 2026.

• For the quarter ending Q1 2026, Current Leases rose 9.58% year-over-year to $2.0 million; the trailing twelve-month figure through Mar 2026 stood at $2.0 million (up 9.58% YoY), and the FY2025 full-year result was $2.0 million, up 12.03% from the prior year.
• Current Leases for Q1 2026 stood at $2.0 million, up from $2.0 million in the prior quarter.
• Across five years, Current Leases topped out at $2.0 million in Q1 2026 and bottomed at $1.4 million in Q1 2022.
• The 5-year median for Current Leases is $1.7 million (2024), against an average of $1.7 million.
• The widest annual swing landed in 2022, when Current Leases jumped 61.52%; it then climbed 1.63% in 2024.
• A 5-year view of Current Leases shows it stood at $1.7 million in 2022, then rose by 1.66% to $1.7 million in 2023, then advanced by 1.63% to $1.7 million in 2024, then gained by 12.03% to $2.0 million in 2025, then grew by 0.56% to $2.0 million in 2026.
• The last three Current Leases figures came in at $2.0 million (Q1 2026), $2.0 million (Q4 2025), and $1.9 million (Q3 2025), per Business Quant data.

Peer Comparison